Chongqing Zhifei Biological Products (300122.SZ) Receives Clinical Trial Approval for Acellular Pertussis-Diphtheria-Tetanus (Component) Combination Vaccine for Adults and Adolescents

Stock News11-11

Chongqing Zhifei Biological Products Co., Ltd. (300122.SZ) announced that its wholly-owned subsidiary, Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for clinical trials of its acellular pertussis-diphtheria-tetanus (component) combination vaccine for adults and adolescents (referred to as the "Adolescent and Adult Component DTaP Vaccine"). The approval notice (No. 2025LP02971) permits the commencement of clinical trials to evaluate the vaccine's efficacy in preventing infections caused by diphtheria, tetanus, and pertussis. The company stated it will promptly initiate the required clinical trials in accordance with the approval notice.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1102222580?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-11 16:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1102222580","market":"other","top_or_hot":-1,"title":"Chongqing Zhifei Biological Products (300122.SZ) Receives Clinical Trial Approval for Acellular Pertussis-Diphtheria-Tetanus (Component) Combination Vaccine for Adults and Adolescents","media":"Stock News","content":"<p>Chongqing Zhifei Biological Products Co., Ltd. (300122.SZ) announced that its wholly-owned subsidiary, Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for clinical trials of its acellular pertussis-diphtheria-tetanus (component) combination vaccine for adults and adolescents (referred to as the \"Adolescent and Adult Component DTaP Vaccine\"). The approval notice (No. 2025LP02971) permits the commencement of clinical trials to evaluate the vaccine's efficacy in preventing infections caused by diphtheria, tetanus, and pertussis. The company stated it will promptly initiate the required clinical trials in accordance with the approval notice.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Chongqing Zhifei Biological Products (300122.SZ) Receives Clinical Trial Approval for Acellular Pertussis-Diphtheria-Tetanus (Component) Combination Vaccine for Adults and Adolescents</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChongqing Zhifei Biological Products (300122.SZ) Receives Clinical Trial Approval for Acellular Pertussis-Diphtheria-Tetanus (Component) Combination Vaccine for Adults and Adolescents\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-11-11 16:56</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Chongqing Zhifei Biological Products Co., Ltd. (300122.SZ) announced that its wholly-owned subsidiary, Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for clinical trials of its acellular pertussis-diphtheria-tetanus (component) combination vaccine for adults and adolescents (referred to as the \"Adolescent and Adult Component DTaP Vaccine\"). The approval notice (No. 2025LP02971) permits the commencement of clinical trials to evaluate the vaccine's efficacy in preventing infections caused by diphtheria, tetanus, and pertussis. The company stated it will promptly initiate the required clinical trials in accordance with the approval notice.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0077","symbol_name":"质押式回购","start_time":0,"source_url":"","article_id":"1102222580","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1102222580","pubTimestamp":1762851379,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Chongqing Zhifei Biological Products Co., Ltd. (300122.SZ) announced that its wholly-owned subsidiary, Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd., has received approval from the National...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"300122":"智飞生物","BK0077":"质押式回购","LU2580892862.HKD":"FRANKLIN SEALAND CHINA A-SHARES \"A\" (HKD) ACC","BK0196":"行业龙头","LU1328615791.USD":"FULLERTON LUX FUNDS - ALL CHINA EQUITIES \"I\" (USD) ACC","BK0046":"生物疫苗","LU1064130708.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"I\" (USD) ACC","LU1064131003.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"A\" (USD) ACC","LU2148510915.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"R\" (USD) ACC","BK0239":"医药制造","LU2580892789.USD":"FRANKLIN SEALAND CHINA A-SHARES \"A\" (USD) ACC","BK0188":"融资融券"},"translate_title":"重庆智飞生物制品（300122.SZ）成人和青少年无细胞百日咳-白喉-破伤风（组分）联合疫苗获临床试验批件","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"300122":1},"content_text":"Chongqing Zhifei Biological Products Co., Ltd. (300122.SZ) announced that its wholly-owned subsidiary, Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for clinical trials of its acellular pertussis-diphtheria-tetanus (component) combination vaccine for adults and adolescents (referred to as the \"Adolescent and Adult Component DTaP Vaccine\"). The approval notice (No. 2025LP02971) permits the commencement of clinical trials to evaluate the vaccine's efficacy in preventing infections caused by diphtheria, tetanus, and pertussis. The company stated it will promptly initiate the required clinical trials in accordance with the approval notice.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1102222580","isCrawlerRequest":true}